From Yahoo Finance: 2025-04-02 12:43:00

Pfizer’s stock struggles post-COVID, facing challenges from expiring patents and generic competition. The FDA shakeup adds further uncertainty for biopharma companies. Allegations of withholding vaccine trial results could lead to legal consequences and damage public trust. Pfizer’s future growth prospects remain uncertain amidst regulatory and competitive pressures.

The resignation of FDA vaccine regulator Dr. Peter Marks raises concerns for vaccine developers like Pfizer and Moderna. Pfizer’s revenue heavily relies on COVID products, and regulatory changes may hinder future commercialization efforts. Despite strong revenue in 2024, Pfizer faces challenges replacing lost revenues and navigating regulatory hurdles.

Pfizer projects flat revenue growth for 2025, impacted by regulatory changes and decreased reimbursement for some drugs. The acquisition of Seagen is beginning to pay off, but Pfizer must invest in R&D to maintain growth. Analysts cautiously rate Pfizer a Moderate Buy, with a price target indicating potential upside, but looming challenges temper optimism.

Pfizer faces a complex environment with regulatory changes impacting its future. While some products show promise, patent cliffs and regulatory hurdles pose significant challenges. Despite a seemingly low valuation, Pfizer’s growth is projected to stagnate or decline in the coming years, raising caution for investors.

Read more: Potential Stock Woe Ahead as Pfizer (PFE) Riles Donald Trump